Masaru Mimura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Masaru Mimura has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Hiroyuki Uchida
Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
2 shared publications Akihiro Fujimoto
Medical Headquarters, Eisai Co., Ltd, Tokyo, Japan
1 shared publicationAkihiro Koreki
Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
1 shared publicationAkira Ninomiya
Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
1 shared publicationAnna Kubota
Department of Health Policy and Management, Keio University School of Medicine, Tokyo, Japan
1 shared publication- Atsuo Nakagawa
Department of Neuropsychiatry St. Marianna University School of Medicine Kawasaki Japan
1 shared publication
Latest Publications
- Open Access
- 20 March 2026
- Published by Elsevier in Journal of Affective Disorders
- Vol. 405, 121632
Differential effects of cognitive behavioral therapy and pharmacotherapy on cognitive function in patients with major depressive disorder: A propensity-weighted longitudinal study
- 20 March 2026
- Published by Elsevier in Journal of Affective Disorders
- Vol. 405, 121632
Open AccessDifferential effects of cognitive behavioral therapy and pharmacotherapy on cognitive function in patients with major depressive disorder: A propensity-weighted longitudinal study
- Open Access
- 20 June 2025
- Published by Wiley in Psychiatry and Clinical Neurosciences Reports
- Vol. 4 (2) , e70126
Impact of brain damage on moral judgment
Aim: This study aimed to determine the effects of damage to various brain regions on moral judgment using a novel third‐party punishment task with fully manipulated conditions.Methods: We assessed 35 individuals with brain damage (26 with frontal lobe and nine with non‐frontal lobe damage) and 30 healthy controls (HCs) using a moral judgment task consisting of 40 vignettes across five conditions, with varying degrees of intentionality and consequences. Participants rated the protagonist's “badness” and their aroused feelings. Cognitive impairments and empathetic traits were also assessed.Results: Compared to HCs, individuals with brain damage judged protagonists to be more blameworthy than did HCs in vignettes where harmful intentions were absent (No Negligence, p = 0.02; No Harm, p = 0.02). The order of moral judgment ratings across conditions was consistent between groups, indicating preserved knowledge of social/moral norms in brain‐damaged individuals. Although these are preliminary results, there are no significant differences in moral judgment ratings between individuals with frontal and non‐frontal lobe damage.Conclusion: This study revealed that individuals with damage to diverse brain regions show excessive punitive tendencies toward the actions of others without malicious intention. These effects cannot be fully explained by changes in empathy or emotional responses. Moral judgment ratings did not significantly differ between individuals with frontal and non‐frontal lobe damage. However, given the small sample size of the non‐frontal lesion group, these findings should be interpreted with caution, and further research is necessary to confirm this conclusion.
- 20 June 2025
- Published by Wiley in Psychiatry and Clinical Neurosciences Reports
- Vol. 4 (2) , e70126
Open AccessImpact of brain damage on moral judgment
Aim: This study aimed to determine the effects of damage to various brain regions on moral judgment using a novel third‐party punishment task with fully manipulated conditions.Methods: We assessed 35 individuals with brain damage (26 with frontal lobe and nine with non‐frontal lobe damage) and 30 healthy controls (HCs) using a moral judgment task consisting of 40 vignettes across five conditions, with varying degrees of intentionality and consequences. Participants rated the protagonist's “badness” and their aroused feelings. Cognitive impairments and empathetic traits were also assessed.Results: Compared to HCs, individuals with brain damage judged protagonists to be more blameworthy than did HCs in vignettes where harmful intentions were absent (No Negligence, p = 0.02; No Harm, p = 0.02). The order of moral judgment ratings across conditions was consistent between groups, indicating preserved knowledge of social/moral norms in brain‐damaged individuals. Although these are preliminary results, there are no significant differences in moral judgment ratings between individuals with frontal and non‐frontal lobe damage.Conclusion: This study revealed that individuals with damage to diverse brain regions show excessive punitive tendencies toward the actions of others without malicious intention. These effects cannot be fully explained by changes in empathy or emotional responses. Moral judgment ratings did not significantly differ between individuals with frontal and non‐frontal lobe damage. However, given the small sample size of the non‐frontal lesion group, these findings should be interpreted with caution, and further research is necessary to confirm this conclusion.
- Open Access
- 30 September 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-10
The association between salivary IL-6 and poor sleep quality assessed using Apple watches in stressed workers in Japan
Insomnia is a major concern among stressed workers worldwide. Although stress generally has a detrimental effect on sleep quality, the impact of biological stress, especially the immunological stress response, on sleep quality is not yet fully understood. Stressed workers were recruited through a screening process using a Brief Job Stress Questionnaire. The participants were asked to complete various occupation-related questionnaires. Additionally, saliva samples were collected to assess interleukin-6 (IL-6) levels as an immunological stress response. Subsequently, they were asked to wear an Apple Watch to record their sleep pattern for one week. Their sleep architecture was estimated using a previously published and validated method. Finally, data from 73 participants were analyzed. Our multivariable analysis revealed that shorter durations of slow-wave sleep (non-rapid eye movement sleep stage 3) were significantly associated with elevated IL-6 levels (p = 0.005) and greater daytime sleepiness (p = 0.002) after controlling for total sleep time. Our finding that a higher immunological stress response is associated with poor sleep quality contributes to a better understanding of insomnia in stressed workers and emphasizes the importance of stress management in this population.
- 30 September 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-10
Open AccessThe association between salivary IL-6 and poor sleep quality assessed using Apple watches in stressed workers in Japan
Insomnia is a major concern among stressed workers worldwide. Although stress generally has a detrimental effect on sleep quality, the impact of biological stress, especially the immunological stress response, on sleep quality is not yet fully understood. Stressed workers were recruited through a screening process using a Brief Job Stress Questionnaire. The participants were asked to complete various occupation-related questionnaires. Additionally, saliva samples were collected to assess interleukin-6 (IL-6) levels as an immunological stress response. Subsequently, they were asked to wear an Apple Watch to record their sleep pattern for one week. Their sleep architecture was estimated using a previously published and validated method. Finally, data from 73 participants were analyzed. Our multivariable analysis revealed that shorter durations of slow-wave sleep (non-rapid eye movement sleep stage 3) were significantly associated with elevated IL-6 levels (p = 0.005) and greater daytime sleepiness (p = 0.002) after controlling for total sleep time. Our finding that a higher immunological stress response is associated with poor sleep quality contributes to a better understanding of insomnia in stressed workers and emphasizes the importance of stress management in this population.
- 2 September 2024
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 78 (9) , 490
Dementia treatment and prevention in the era of 60 million patients: advancing disease‐modifying therapies faster, wider, and deeper
- 2 September 2024
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 78 (9) , 490
Dementia treatment and prevention in the era of 60 million patients: advancing disease‐modifying therapies faster, wider, and deeper
- Open Access
- 1 December 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (48) , e36191
Patient prognosis and prediction model for taking Kampo formulas in dysmenorrhea: An observational study
Two representative Kampo formulas, keishibukuryogan and tokishakuyakusan, are frequently prescribed for patients with dysmenorrhea. We previously constructed a model that could predict which of these 2 formulas was most suitable, which is based on 4 subjective symptoms and 3 objective signs. To evaluate the prognosis of patients with dysmenorrhea using the established prediction model and assess the treatment outcomes between those treated in accordance with the prediction model and those who received various other treatments. In this retrospective, observational study, we included patients with menstrual pain who visited the Kampo Clinic at the Keio University Hospital for the first time between October 2014 and December 2020. These patients were monitored over a 90-day follow-up period. Participants were categorized into 2 groups: model-accordance and various-options. The progression of visual analogue scale (VAS) values was evaluated by determining the slopes from regression analysis between these 2 groups, with changes corroborated by the medical records. The study comprised 57 patients: 37 in the model-accordance group and 20 in the various-options group. Notably, the various-options group reported a significantly higher number of subjective symptoms (P = .03). The VAS value showed a decline, as indicated by the negative slope value of the regression line, across both groups – irrespective of their classification. There were no significant differences in the occurrence of adverse events between the 2 groups. The prognosis of patients with dysmenorrhea and the incidence of adverse events remained consistent, regardless of whether the treatment approach was in accordance with the prediction model or varied. Further studies are warranted to assess the prognosis when Kampo formulas are chosen based on the prediction model in the various-options population.
- 1 December 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (48) , e36191
Open AccessPatient prognosis and prediction model for taking Kampo formulas in dysmenorrhea: An observational study
Two representative Kampo formulas, keishibukuryogan and tokishakuyakusan, are frequently prescribed for patients with dysmenorrhea. We previously constructed a model that could predict which of these 2 formulas was most suitable, which is based on 4 subjective symptoms and 3 objective signs. To evaluate the prognosis of patients with dysmenorrhea using the established prediction model and assess the treatment outcomes between those treated in accordance with the prediction model and those who received various other treatments. In this retrospective, observational study, we included patients with menstrual pain who visited the Kampo Clinic at the Keio University Hospital for the first time between October 2014 and December 2020. These patients were monitored over a 90-day follow-up period. Participants were categorized into 2 groups: model-accordance and various-options. The progression of visual analogue scale (VAS) values was evaluated by determining the slopes from regression analysis between these 2 groups, with changes corroborated by the medical records. The study comprised 57 patients: 37 in the model-accordance group and 20 in the various-options group. Notably, the various-options group reported a significantly higher number of subjective symptoms (P = .03). The VAS value showed a decline, as indicated by the negative slope value of the regression line, across both groups – irrespective of their classification. There were no significant differences in the occurrence of adverse events between the 2 groups. The prognosis of patients with dysmenorrhea and the incidence of adverse events remained consistent, regardless of whether the treatment approach was in accordance with the prediction model or varied. Further studies are warranted to assess the prognosis when Kampo formulas are chosen based on the prediction model in the various-options population.